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http://dx.doi.org/10.1016/j.ccr.2013.12.010SUMMARYCurrent antiangiogenic therapy is limited by its cytostatic nature and systemic side effects. To address these
limitations, we have unveiled the role of RhoJ, an endothelial-enriched Rho GTPase, during tumor progres-
sion. RhoJ blockade provides a double assault on tumor vessels by both inhibiting tumor angiogenesis and
disrupting the preformed tumor vessels through the activation of the RhoA-ROCK (Rho kinase) signaling
pathway in tumor endothelial cells, consequently resulting in a functional failure of tumor vasculatures. More-
over, enhanced anticancer effects were observedwhen RhoJ blockadewas employed in concert with a cyto-
toxic chemotherapeutic agent, angiogenesis-inhibiting agent, or vascular-disrupting agent. These results
identify RhoJ blockade as a selective and effective therapeutic strategy for targeting tumor vasculature
with minimal side effects.INTRODUCTION
Tumor angiogenesis is a prerequisite for tumor progression (Fer-
rara and Alitalo, 1999; Hanahan and Folkman, 1996). The angio-
genic switch is activated during tumor growth, and the resulting
tumor neovessels manage the O2 and nutrient requirements as
well as the clearance of CO2 andmetabolite in tumor tissue (Car-
meliet and Jain, 2011; Hanahan and Folkman, 1996). Moreover,
the tumor vasculature is one of the main routes of tumor cell
metastasis to distant organs (Hanahan and Weinberg, 2011).
Collectively, these observations imply that tumors cannot grow
further and metastasize without sufficient blood supply. This
inference has led to the development of various angiogenesis-Significance
Vascular targeting therapies have been considered as one of th
ever, the survival benefit is usually only several months, depe
and evasive mechanisms. Here, we show the potential of RhoJ
of existing vessels in tumors, to be a powerful adjuvant option
ventional antiangiogenic and vascular-disrupting agents. Our s
hibitors against RhoJ.
102 Cancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc.inhibiting agents (AIAs) in the past decade (Ellis and Hicklin,
2008; Ferrara and Kerbel, 2005; Sennino and McDonald,
2012), many of which target vascular endothelial growth factor
(VEGF) and its receptors and have proved to be effective in clin-
ical practice (Carmeliet and Jain, 2011; Chung et al., 2010). In
addition, ongoing drug development has focused onmoderating
other angiogenic pathways (Bono et al., 2013; Gerald et al.,
2013; Koh et al., 2010; Sennino and McDonald, 2012; Tvorogov
et al., 2010). Because current AIAs are inherently cytostatic and
target newly growing tumor vasculature, they are more suited to
tumor stabilization than to the regression of a bulky tumor (Ellis
and Hicklin, 2008; Horsman and Siemann, 2006). Even after
repeated cycles of AIA treatment, a substantial amount ofe anticancer therapeutic options for the past decade. How-
nding on clinical conditions, because of intrinsic resistance
blockade, through inhibition of angiogenesis and disruption
to complement and maximize the anticancer effects of con-
tudy provides a rationale for the development of specific in-
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Targeting RhoJ for Tumor Vascular Disruptionpreformed vasculature remains intact within the tumor. In addi-
tion, although it requires further investigation in clinics, several
preclinical studies suggested that tumor cells could convert to
a more aggressive phenotype with increased invasion and
metastasis after the AIA treatment (Bergers and Hanahan,
2008; Casanovas et al., 2005; Ebos and Kerbel, 2011).Moreover,
because VEGF and its receptors are expressed ubiquitously in
normal tissues and in tumors, current AIAs produce adverse
effects such as hypertension, proteinuria, and hemorrhage
(Chen and Cleck, 2009; Kamba andMcDonald, 2007). Therefore,
it is important to better discern differences between tumor and
normal vasculature in order to developmore selective and potent
targeting strategies.
Rho GTPases have recently been discovered as fine tuners
of vascular morphogenesis and homeostasis (Bryan and
D’Amore, 2007). Rho GTPases are considered as essential
downstream targets of VEGF signaling in endothelial cells
(ECs), and a well-controlled balance between different Rho
GTPases governs almost all aspects of angiogenic processes
such as EC migration, proliferation, extracellular matrix degra-
dation, vascular morphogenesis, and vascular integrity
(Beckers et al., 2010; Bryan and D’Amore, 2007; van der
Meel et al., 2011). Although much remains to be unraveled
about how different Rho GTPases are involved in angiogenesis
and coordinate with each other, targeting Rho GTPases has
become a promising strategy to enhance current antiangio-
genic treatment (van der Meel et al., 2011). One question to
be answered is which Rho GTPase is the most promising
antiangiogenic target with high selectivity against tumor
vasculature.
RhoJ is a Rho GTPase mainly expressed in ECs (Fukushima
et al., 2011; Kaur et al., 2011; Takase et al., 2012; Yuan et al.,
2011), and its expression is regulated by the endothelial
transcription factor ERG in primary cultured human umbilical
vein ECs (HUVECs) (Yuan et al., 2011). Despite its vascular
expression pattern, the importance of RhoJ in vascular biology
is only beginning to emerge. A few recent papers have revealed
that RhoJ is an important regulator of EC motility and tube
morphogenesis in three-dimensional matrices (Kaur et al.,
2011; Yuan et al., 2011). During development, RhoJ is specif-
ically expressed in the dorsal aorta and intersomitic vessels
of mouse embryos as well as in the retinal vessels of the
postnatal mouse (Fukushima et al., 2011; Kaur et al., 2011).
RhoJ-deficient mice display delayed radial growth of retinal
vasculature during postnatal development with increased
vascular regression in the vascular front (Takase et al., 2012).
Also, RhoJ-overexpressing mice attenuate the aberrant
extraretinal vascular outgrowth in an oxygen-induced retinop-
athy model (Fukushima et al., 2011). Thus, RhoJ signaling
primarily affects vessel remodeling via balancing neovessel
formation and regression; however, the expression and func-
tion of RhoJ in tumor angiogenesis have not been elucidated
thus far.
Because RhoJ is specifically expressed in ECs during devel-
opment (Fukushima et al., 2011; Kaur et al., 2011; Leszczynska
et al., 2011), we speculated that it is also expressed in the
growing tumor vasculature. Here, we investigated the biological
role and therapeutic relevance of targeting RhoJ in various solid
tumor models.CRESULTS
High Expression of RhoJ in Tumor ECs during Tumor
Progression
To unveil the role of RhoJ in tumor progression, we generated
RhojGFP/GFP (RhoJ-KO) mice, in which Rhoj is knocked out by
replacing its exon 1 with GFP; with this construct, GFP is
expressed instead of Rhoj under the transcriptional control of
the Rhoj promoter (Figures S1A–S1C available online). To
monitor RhoJ expression in tumor tissues, RhojGFP/+ mice were
implanted with Lewis lung carcinoma (LLC) and B16F10 mela-
noma cells. To observe RhoJ expression in a spontaneous
breast tumor model, we generated MMTV-PyMT/RhojGFP/+
mice (P/Rhoj GFP/+) by mating RhojGFP/+ mice with MMTV-
PyMT mice. The LLC tumor and B16F10 melanoma displayed
high RhoJ expression in tumor vessels 7 days after implantation,
and spontaneous breast tumors of P/RhojGFP/+ also showed
strong RhoJ expression in tumor vessels 12 weeks after birth
(Figure 1A). In contrast to robust expression in tumor vessels,
RhoJ expression was not observed in the lymphatic vessels of
tumors and lymph nodes (LNs). High-magnification analyses of
the LLC tumor revealed that RhoJ expression was mainly
confined to tumor ECs, whereas some non-ECs such as perivas-
cular mural cells and tumor stromal cells also occasionally
expressed RhoJ (Figure 1B). Quantitative RT-PCR analysis of
purified cells from LLC tumors showed that they consistently
exhibited a predominant expression of RhoJ in CD31+CD45
tumor ECs with a weak expression in CD31CD45 cells, but
no expression in CD31CD45+ hematopoietic cells (Figure 1C).
To identify RhoJ-expressing stromal cells other than ECs,
GFP+ and GFP cells were purified from the CD31CD45 cells
of P/Rhoj GFP/+ tumors using fluorescence-activated cell sorting
(Figure S1D). We discovered that these RhoJ-expressing non-
ECs highly expressed platelet-derived growth factor (PDGFR)a,
PDGFRb, a-SMA, and FSP-1, indicating that these cells could
be pericytes and cancer-associated fibroblasts (Figure S1E). In
tumor vasculature, RhoJ expression follows a distinct spatio-
temporal regulation. It is most robustly expressed during early
tumorigenesis, in contrast to being attenuated in later stages of
tumor growth (Figures 1C–1E). Moreover, RhoJ is intensively
expressed in the peritumoral high-angiogenic region compared
to the intratumoral regions of various tumors (Figures 1F, 1G,
and S1F). Intriguingly, RhoJ expression in normal tissues of adult
mice is very infrequent and indistinct, only occasionally present
in heart blood vessels and stromal cells and in LN blood vessels
(Figure S1G). RhoJ-KOmice grew to adulthood normally without
any growth retardation or vascular abnormalities in major organs
including heart, lung, kidney, and liver (Figure S1H). Also, there
were no differences in vascular morphology and integrity be-
tween RhoJ-KO mice and wild-type (WT) mice (Figures S1I–
S1O). These findings suggest that RhoJ is a potential candidate
for a more selective vascular targeting therapy with attenuated
systemic side effects compared to current AIA therapies.
To examine the relevance of RhoJ in human tumor angiogen-
esis, we assessed RhoJ expression in human tissues and
confirmed that RhoJ is highly expressed in the tumor vessels of
colon adenocarcinomas (7 of 12 samples), but it is undetectable
in normal colon tissues (0 of 10 samples) (Figure 1H). Furthermore,
we analyzed the RhoJ expression using the 216 colon cancerancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc. 103
Figure 1. RhoJ Is Highly Expressed in Tumor ECs during Tumor Progression
Unless otherwise denoted: scale bars, 100 mm. Each group: n = 5. Values are mean ± SD. Dotted lines indicate the boundaries between the skin and tumor.
(A) Images showing RhoJ expressions (green) in CD31+ tumor vessels of LLC and B16F10 tumors at day 7 after implantation into RhojGFP/+ mice and in those of
spontaneous breast cancer of 12-week-old P/Rhoj GFP/+ mice. Each indicated region (squares) is magnified in the lower panel.
(B) Magnified image showing localization of RhoJ expression in LLC tumor at day 7. Note that the expression of RhoJ is mainly confined to tumor ECs (yellow
arrowheads), but perivascular mural cells (white arrowheads) and tumor stromal cells (white arrows) also occasionally express RhoJ.
(C) Comparisons of RhoJ mRNA expressions in the CD31+CD45 ECs (tECs), CD31CD45+ hematopoietic cells (tHCs), and CD31CD45 other cells (tOCs) of
LLC tumor at indicated days. Each group: n = 4. *p < 0.05 versus day 7.
(D and E) Temporal changes of RhoJ expressions at indicated days of LLC tumor. The RhoJ-GFP+ area is presented as a percent per CD31+ area. *p < 0.05
versus day 7.
(F and G) Spatial changes of RhoJ expressions in peri- and intratumoral regions of various tumors at indicated days. The RhoJ-GFP+ area is presented as a
perecent per CD31+ area. *p < 0.05 versus each peritumoral region.
(H) Images showing RhoJ+CD144+ tumor vessels (arrow) in human colon cancer tissue and RhoJCD144+ normal vessels in adjacent normal colon tissue. Scale
bars, 20 mm.
(I–K) From the TCGA database, a total of 216 colon cancer patients were divided into RhoJ-high (n = 78) or RhoJ-low (n = 138) groups in which the cut-off value
was the average RhoJ expression level of all patients.
(I) Prevalence of lymphovascular invasion in the colon cancer patients with high or low expression of RhoJ. p = 0.017.
(J) Kaplan-Meier survival analysis of the colon cancer patients with high or low expression of RhoJ. p = 0.033.
(K) Correlation plot between RhoJ expression level and the number of metastatic LNs in the colon cancer patients. p = 0.006 and R2 = 0.196.
See also Figure S1 and Table S1.
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cancergenome.nih.gov) (Table S1) and found that the patients
that had tumors with high RhoJ expression had increased preva-
lenceof lymphovascular invasion (Figure1I) anddecreasedoverall
survival after the diagnosis of colon cancer (Figure 1J). Finally, the
RhoJ expression positively correlated with the number of meta-
static LNs (Figure 1K), suggesting the possible positive correlation
of RhoJ with human cancer progression.104 Cancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc.RhoJ Deletion Suppresses Tumor Growth, Neovessel
Formation, and Metastasis in the LLC Tumor
Taking the advantage that RhoJ-KO mice grew to adulthood
normally, we used RhoJ-KO mice to address the role of RhoJ
during tumor progression. We employed the LLC tumor model
by subcutaneously (s.c.) injecting LLC cells into RhoJ-WT and
KO mice. At 3 weeks after implantation, compared to WT
mice, RhoJ-KO mice showed a 55% reduction in tumor growth
Cancer Cell
Targeting RhoJ for Tumor Vascular Disruption(Figure 2A), which was most prominent during early growth (Fig-
ure 2B). Tumors had an increased occurrence of hemorrhagic
foci in RhoJ-KO mice (Figure 2C), in which the intratumoral
hemorrhagic area was 61% higher than WT (Figure 2D). More-
over, hypoxia was more apparent with extensive apoptosis in
the center of the tumor in RhoJ-KO mice (Figures 2E and 2F).
To further evaluate the impact of RhoJ deletion on tumor angio-
genesis, we investigated tumor vessels 2 weeks after implanta-
tion. Compared to RhoJ-WT mice, tumor vascular densities in
RhoJ-KO mice were 36% and 37% less in the peri- and intratu-
moral regions, respectively (Figures 2G and 2H), whereas there
were no differences in the distribution and densities of lymphatic
vessels at the peritumoral regions and sentinel LNs (Figures S2A
and S2B). Most importantly, tumor vascular sprouting was 72%
lower in RhoJ-KO mice (Figures 2I and 2J), suggesting that
RhoJ is crucial in neovessel formation by promoting sprouting
angiogenesis. Finally, to examine the role of RhoJ in tumor
metastasis, we harvested inguinal LNs and whole lungs of the
tumor-bearing mice 3 weeks after tumor implantation. The
analyses showed 66% less metastasized LLC tumor cells in
the LNs of RhoJ-KO mice (Figures 2K and 2L). Moreover, the
number of metastatic tumor colonies (>100 mm in diameter in
tumor sections) in the lungs was 51% less in RhoJ-KOmice (Fig-
ures 2M and 2N).
RhoJ Deletion Disrupts Tumor Vascular Integrity and
Function
Tumor vasculature consists of malformed, disintegrated, leaky,
and highly branched vessels that continuously undergo vascular
remodeling (McDonald and Baluk, 2002; Siemann, 2011; Tre´dan
et al., 2007). Because RhoJ-KO mice displayed increased intra-
tumoral hemorrhage compared to RhoJ-WT mice, we further
investigated the role of RhoJ in vascular integrity and function.
Interestingly, the LLC tumor of RhoJ-KO mice had more disrup-
ted tumor vessels (Figure 3A) and reduced vascular density (Fig-
ure 3B) in the center. Together with this observation, coverage of
a-SMA+ mural cells alongside tumor vessels was 33% less (Fig-
ures 3C and 3D), and collagen type IV+ basement membrane
(BM) coverage was reduced by 71% in tumor vessels of RhoJ-
KOmice (Figures 3E and 3F), revealing that RhoJ-KO tumor ves-
sels were more disintegrated with severe loss of pericytes and
BM components. Consistent with these findings, RhoJ-KO
tumor vessels displayed a 67% increased intratumoral hemor-
rhage (Figures 3G and 3H) and more than a 2-fold increase in
dextran leakage where dextran was intravenously (i.v.) injected
(Figures 3I and 3J), indicating a significant increase in tumor
vascular permeability. Next, we evaluated the functionality of
tumor vessels by i.v. injecting lectin. Tumor vascular perfusion
was profoundly impeded by 81% in tumors of RhoJ-KO mice
(Figures 3K and 3L). Altogether, these findings suggest that
RhoJ-deficient tumor vessels aremore disintegrated and perme-
able than typical tumor vessels and that the increased extravasa-
tion and hemorrhage eventually lead to severely retarded blood
flow into tumor tissues (Figure 3M). This scenario is quite compa-
rable with the ‘‘vascular shutdown’’ phenomenon caused by
vascular-disrupting agents (VDAs) (Tozer et al., 2005).
To determine whether RhoJ deletion affects tumor progres-
sion broadly, we also evaluated the melanoma model by s.c.
implantation of B16F10 cells into RhoJ-WT and KO mice.CConsistent with the findings observed in LLC tumors, tumor
growth was delayed by 52% in RhoJ-KO mice compared to
RhoJ-WT mice (Figures S3A and S3B). In terms of tumor angio-
genesis, vascular densities were reduced by 31% and 28% in
the peri- and intratumoral regions of Rho-KO mice, respectively
(Figures S3C and S3D). Moreover, lymphatic metastasis of
tumor cells into inguinal LNs was suppressed by 47% in RhoJ-
KO mice (Figures S3E and S3F).
RhoJ Deletion Also Reduces Tumor Growth, Neovessel
Formation, and Metastasis in the Spontaneous Breast
Cancer Model
As for the spontaneous tumor model, MMTV-PyMT mice were
mated with RhojGFP/+ mice to generate MMTV-PyMT;Rhoj+/+
mice (P/RhoJ-WT) and MMTV-PyMT;RhojGFP/GFP mice (P/
RhoJ-KO). At 14 weeks of age, P/RhoJ-KO showed reduced
development of spontaneous mammary tumor nodules
compared to P/RhoJ-WT (Figure 4A). In the P/RhoJ-KO,
compared to those in P/RhoJ-WT, median time to palpable
tumor development was delayed by 2 weeks (Figure 4B), and
the number of tumor nodules per mouse decreased 32%–41%
(Figure 4C). Moreover, the average size and tumor burden of
P/RhoJ-KO mice were 61% and 64% less, respectively, than
those of P/RhoJ-WT mice (Figures 4D and 4E). Histological ex-
amination showed that there were more noninvasive carcinoma
lesions with well-preserved tumor margins in the peritumoral
regions of P/RhoJ-KO (Figure 4F, see legend for a detailed
explanation), which indicates that RhoJ deficiency delays tumor
progression and invasion. Also, in P/RhoJ-KO, vascular den-
sities were 35% and 41% less (Figures 4G and 4H) and tumor
vascular sprouting was 59% and 42% less (Figure 4I) in the
peri- and intratumoral regions, respectively, compared to P/
RhoJ-WT. Furthermore, morphology of tumor vasculatures in
the intratumoral regions of P/RhoJ-KO seemed more disrupted
(Figure 4G). Consistent with their disintegrated morphology,
extravasation of i.v.-injected dextran was 2.5-fold greater in
the tumor vessels of P/RhoJ-KO (Figures 4J and 4K), indicating
that P/RhoJ-KO tumor vessels are highly permeable compared
to those of P/RhoJ-WT. In addition, PDGFRb+ pericyte support
was 62% less (Figures 4L and 4M) and the track of collagen
type IV+ BM along tumor vessels was 46% less (Figures 4N
and 4O) in P/RhoJ-KO. Finally, the number of metastatic tumor
colonies (>100 mm in diameter in tumor sections) in the lung
was 82% less in P/RhoJ-KO (Figures 4P and 4Q). Taken
together, these results lead us to conclude that RhoJ plays a
crucial role in the formation of tumor neovessels and main-
tenance of tumor vascular integrity, influencing the tumor
progression.
RhoJ Deficiency Delays Wound Healing through
Attenuated Angiogenesis
We also evaluated the role of RhoJ in wound healing using a
punch-wound healing model. Like tumor vessels, the blood ves-
sels in the granulation area of wounds displayed high RhoJ
expression (Figure S4A). Compared to RhoJ-WT mice, RhoJ-
KO mice showed 23% delayed wound closure, 48% reduced
vascular density, and 39% decreased granulation area in the
wound regions (Figures S4B–S4G). Thus, RhoJ plays a positive
angiogenic role in wound healing.ancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc. 105
Figure 2. RhoJ Deletion Inhibits Tumor Growth, Neovessel Formation, and Metastasis in LLC Tumors
Three weeks after implantation of LLC cells into RhoJ-WT and -KO mice, histological analyses were performed. Unless otherwise denoted: scale bars, 100 mm.
Each group: n = 6. Values are mean ± SD. *p < 0.05 versus RhoJ-WT.
(A and B) Comparisons of tumor volume (A) and growth rate (B). Each group: n = 10.
(C) Tumor sections stained with H&E. Arrows indicate hemorrhagic lesions. Scale bar, 5 mm.
(legend continued on next page)
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Tumor Angiogenesis and Disrupts Tumor Vessel
Integrity
To ascertain the role of RhoJ in tumor ECs during tumor
angiogenesis, we generated inducible EC-specific RhoJ loss-
of-function mice (RhoJ-KOEC) by mating Rhojfl/fl with
Cdh5(PAC)-CreERT2 (Wang et al., 2010), in which the Rhoj allele
was efficiently deleted in the ECs upon tamoxifen administration
(Figures S5A–S5C). Rhojfl/fl mice (RhoJ-WTEC) were used as
control. Compared to those in RhoJ-WTEC, LLC tumors showed
38% reduced growth in RhoJ-KOEC (Figure 5A) and remarkable
intratumoral hemorrhagic necrosis 16 days after LLC tumor
implantation (Figure 5B), in which the hemorrhagic area was 3-
fold larger and viable tumor areas were 35% less (Figures 5C
and 5D). The impact of EC-specific Rhoj deletion on tumor
growth was 31% less compared to global Rhoj deletion, which
is attributed by the 70% deletion of RhoJ in tumor ECs (Fig-
ure S5C). Vascular densities of RhoJ-KOEC tumors were 45%
and 43% reduced in the peri- and intratumoral areas, respec-
tively (Figures 5E and 5F). Notably, the morphology of tumor
vessels in the intratumoral core of RhoJ-KOEC was more disrup-
ted (Figure S5D). Additionally, PDGFRb+ pericyte coverage was
reduced by 68% (Figures 5G and 5H), and collagen type IV+ BM
coverage along tumor vessels was 51% diminished (Figures 5I
and 5J) in RhoJ-KOEC. Moreover, the leakage of i.v.-injected
dextran was remarkably increased by 6.8-fold in the intratumoral
core of RhoJ-KOEC (Figures 5K and 5L). Finally, junctional
CD144 expression seemed to be decreased in the intratumoral
regions of RhoJ-KOEC (Figure S5E). We also evaluated the
effect of endothelial RhoJ deletion on established macroscopic
tumors (>300 mm3). The results showed that the tumor
growth was decreased by 34% (Figure 5M) and the overall
survival of mice increased by 25% (Figure 5N), denoting
that RhoJ is a feasible target for further anticancer drug
development even in established tumors. In conclusion, these
findings indicate that RhoJ in tumor ECs is critical to the regula-
tion of tumor angiogenesis and maintenance of tumor vascular
integrity.
RhoJ Regulates EC Motility, Tube Formation, and
Junctional Integrity through Suppression of the RhoA-
ROCK Signaling Pathway
To determine the role of RhoJ in in vitro angiogenesis and
vascular leakage, HUVECs transfected with either RhoJ siRNA
(siJ-ECs) or control siRNA (siC-ECs) were used. To exclude the
off-target effects, five independent RhoJ siRNA were designed,
and three RhoJ siRNAs with the best performance (named J0,
J1, and J2) were chosen for further experiments (Figures S6A(D) Comparison of intratumoral hemorrhagic area. Each group: n = 10.
(E and F) Images showing CD31+ blood vessels, caspase-3+ apoptotic cells, and
90 min before tumor sampling.
(G and H) Images (G) and quantification (H) of blood vessels in the peri- and intra
(I and J) Images (I) and quantification (J) of vascular sprouts (arrows, sprout > 10
(K and L) Images (K) and quantification (L) of cytokeratin+ tumor metastasis in
sectional area. Scale bar, 500 mm.
(M) Lung sections stained with H&E. Four regions were viewed under high magn
(lower).
(N) Comparison of number of metastatic colonies (>100 mm in diameter) per lung
See also Figure S2.
Cand S6B), and their results were averaged (siJ-EC) (see Figure S6
for their individual results). In comparison to those of siC-ECs, a
time-lapse tracking analysis revealed that siJ-ECs displayed
more restricted motility with a 54% reduction in displacement
speed and 27% reduction in trajectory speed (Figures 6A, 6B,
and S6C). Moreover, our established microfluidics assay (Joo
et al., 2012) (Figures S6D and S6E) showed that siJ-ECs had
38% and 50% less migration and angiogenic sprouting, respec-
tively (Figures 6C and 6D), indicating that RhoJ is an important
regulator of EC migration and sprouting. Furthermore, siJ-ECs
on the Matrigel formed poorly connected networks with
decreased numbers of EC junctions and tubules (Figures 6E,
6F, and S6F). In addition, detailed analysis of ECs and EC tubules
showed that siJ-ECs have increased actin stress fiber formation
(Figures 6G and S6G). In agreement with this result, increased
actin stress fiber formation was also observable in the intra-
tumoral vasculatures of RhoJ-KOEC (Figure 6H), confirming the
negative correlation between RhoJ and EC stress fiber formation
(Kaur et al., 2011).
We next questioned whether RhoJ has any role in maintain-
ing EC integrity, because various Rho GTPases are also
involved in endothelial integrity (Beckers et al., 2010; Bryan
and D’Amore, 2007). To answer this question, an in vitro
vascular permeability assay was applied to examine the
changes in EC paracellular integrity (Figure 6I). Compared to
siC-ECs, the vascular permeability across the EC monolayer
was increased by 55% and 134% with or without VEGF-A,
respectively, in siJ-ECs (Figures 6J and S6H). Consistent with
this finding, junctions between ECs were also more loose and
disrupted in siJ-ECs, especially in the presence of VEGF-A (Fig-
ures 6K and 6L). In parallel, tumor blood vessels of RhoJ-KO
mice were also seriously disrupted (Figure S6I). These suggest
that RhoJ works to maintain the integrity of the EC monolayer
and negatively regulates VEGF-A-induced vascular leakage.
Finally, we questioned whether RhoJ is associated with
RhoA-ROCK-myosin signaling, because this signaling is an
important regulator of stress fiber formation and EC contraction
(Sun et al., 2006) and endothelial RhoJ also seemed to be
related to the regulation of stress fibers. Indeed, siJ-ECs had
increased RhoA activity, ROCK activity, and myosin light-
chain phosphorylation, but these almost completely diminished
with the ROCK inhibitor, Y-27632 (Figures 6M and S6J–M),
suggesting that RhoJ is a negative regulator of the RhoA-
ROCK signaling pathway in ECs. Collectively, these findings
indicate that RhoJ plays an important role in EC migration,
tube formation, and maintenance of vascular integrity through
the suppression of the RhoA-ROCK signaling pathway in ECs
(Figure 6N).Hypoxyprobe-1+ hypoxic areas in a tumor. Hypoxyprobe-1 was i.p.-injected
tumoral regions.
mm in length) of tumor vessels. Scale bars, 10 mm.
the inguinal LNs. The cytokeratin+ area was presented as a percent per total
ification. Arrows indicate metastatic foci. Scale bar, 5 mm (upper) and 200 mm
section.
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Figure 3. RhoJ Deletion Disrupts Tumor Vascular Integrity and Function
Two weeks after LLC implantation, tumors of RhoJ-WT and -KO mice were sampled to analyze detailed vascular phenotypes. Unless otherwise denoted: scale
bars, 100 mm. Values are mean ± SD. Each group: n = 5. *p < 0.05.
(A and B) Images (A) and quantification (B) of tumor vessels in the intratumoral center.
(C and D) Images (C) and quantification (D) of a-SMA+mural cell coverage on tumor vessels. Coverage of a-SMA is presented as a percent of length that lies along
CD31+ vessels.
(E and F) Images (E) and quantification (F) of loss of collagen type IV+ BM (red) along tumor vessels (blue). Coverage of collagen type IV is presented as a percent of
length that lies along CD31+ vessels.
(G andH) Images (G) and quantification (H) of Ter-119+ red blood cells (red) extravasated from tumor vessels. The Ter-119+ area is presented as a percent per total
sectional area.
(I and J) Images (I) and quantification (J) of dextran leakage area (red) from tumor vessels. Dextran was i.v.-injected 30 min before sacrifice. Dextran+ area is
presented as a percent per total sectional area.
(K and L) Images (K) and quantification (L) of lectin-perfused (red) tumor vessels. Lectin was i.v.-injected 10 min before sacrifice. Lectin+ area is presented as a
percent per CD31+ area.
(M) Schematic diagram showing the effects of RhoJ deletion on tumor vasculatures. Red arrows indicate the hemorrhage from vessels. EC, endothelial cell; PC,
pericyte; BM, basement membrane; RBC, red blood cell.
See also Figure S3.
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Deleted Mice
To confirm the effect of RhoJ deletion in concert with conven-
tional chemotherapeutic drugs, cisplatin (10 mg/kg) was intra-
peritoneally (i.p.) injected into RhoJ-KO mice once every week
starting when tumor volume exceeded 100mm3. Cisplatin signif-
icantly delayed LLC tumor growth by 90% in RhoJ-KO mice
compared to a 64% decrease in RhoJ-WT mice (Figure S7A).
Histological analyses after cisplatin treatment revealed 80%
increased intratumoral necrosis in RhoJ-KO mice treated with
cisplatin compared to RhoJ-WT mice treated with cisplatin (Fig-
ures S7B and S7C). In fact, intratumoral accumulation of108 Cancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc.cisplatin increased by 2-fold in RhoJ-KO mice compared to
RhoJ-WT mice (Figures S7D and S7E). This may be due to
increased extravasation and retention of cisplatin from the disin-
tegrated tumor vessels at the intratumoral region of RhoJ-KO
mice. These findings indicate that RhoJ blockade in combination
with conventional chemotherapy could yield an enhanced anti-
tumor effect.
Dual Blockade of RhoJ and VEGF-A Signaling Displays a
More Potent Antitumor Effect
Many Rho GTPases are activated by VEGF-A and share their
common downstream effector molecules (Beckers et al., 2010;
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driven activation of other Rho GTPases may partially compen-
sate for the effects of RhoJ ablation, limiting the antitumor effects
of the RhoJ blockade. To resolve this potential problem and
maximize the antitumor effect, we investigated the effect of
VEGF-A blockade in the tumor progression of RhoJ-WT and
KO mice. Administration of VEGF-trap (25 mg/kg) delayed LLC
tumor growth by 88% in RhoJ-KO mice compared to a 47%
decrease in RhoJ-WT mice (Figure 7A). Moreover, VEGF-trap
reduced tumor vascular densities by 66% and 68% in peri-
and intratumoral areas of RhoJ-KO mice, respectively, which
was more potent than the 43% and 49% decrease in RhoJ-WT
mice (Figures 7B and 7C). From these results, we could confirm
the potential of RhoJ blockade as an adjuvant option to enhance
AIA therapies, such as VEGF-trap.
Next, to establish a method for therapeutic blockade of RhoJ,
a tumor-targeted siRNA delivery system (Kim et al., 2012) was
employed. The aptide was designed and used according to a
previous protocol (Figure S7F) (Kim et al., 2012). We chose fibro-
nectin extradomain B (EDB) as the target for the aptide, because
EDB is highly expressed in tumor tissues (Kim et al., 2012;
Menrad and Menssen, 2005). The aptide specific for EDB
(APTEDB) was conjugated with liposome to form an APTEDB-lipo-
some complex, and siRNA was encapsulated within this
APTEDB-liposome complex (Figure S7G). We confirmed the
successful delivery of APTEDB-liposome into LLC tumor tissues
(arrowhead, Figure S7H) and the knockdown of RhoJ with
encapsulated RhoJ siRNA (en-siJ) compared to encapsulated
control siRNA (en-siC) (Figures S7I–S7K). In vivo experiments
showed that the antitumor effect of en-siJ (2 mg/kg) monother-
apy or VEGF-trap (25 mg/kg) monotherapy was similar, showing
a 40%–50% decrease in tumor volume compared to the control
group, while the combination therapy of en-siJ with VEGF-trap
increased this effect to 66% (Figure 7D). Moreover, en-siJ or
VEGF-trap monotherapy decreased tumor vessel densities by
45% and 50% in the peri- and intratumoral regions, respec-
tively, but the combination therapy showed a 66% and 68%
respective reduction (Figures 7E and 7F). Notably, intratumoral
hemorrhage of en-siJ-treated tumors dramatically decreased
with VEGF-trap treatment (Figures 7G and 7H), indicating that
RhoJ blockade induces vascular disruption and hemorrhage in
a VEGF-dependent manner, which is consistent with findings
of the in vitro permeability assay (Figure 6J). Finally, the combi-
nation therapy showed a 75% reduction in LNmetastasis, which
was greater than either en-siJ or VEGF-trap monotherapy (Fig-
ures 7I and 7J). Together, the dual blockade of RhoJ and
VEGF signaling is superior to the single blockade in antitumor,
antiangiogenic, and antimetastatic activity.
RhoJ Blockade Augments the Antitumor Effect of a VDA,
Combretastatin-A4-Phosphate
VDAs are known to disrupt established tumor vessels by directly
targeting the cytoskeletons of ECs (Siemann, 2011). Because
RhoJ blockade is comparable to VDAs in inducing tumor
vascular disruption, we speculated that RhoJ blockade might
have an enhancing effect with VDAs, such as combretastatin-
A4-phosphate (CA4P). The in vitro tube formation assay revealed
that RhoJ knockdown in concert with CA4P (20 nM) treatment
profoundly inhibited EC tube formation, inducing almost com-Cplete disruption, compared to single treatment with either
CA4P or RhoJ siRNA (Figures 8A and 8B). Also, permeability
across the EC monolayer of siJ-ECs treated with CA4P was
increased by 2.9-fold compared to that of siC-ECs treated with
PBS (Figure 8C). Moreover, RhoJ knockdown in combination
with CA4P further activated the RhoA-ROCK signaling pathway
(Figure S8). These suggest a possible collaboration between
RhoJ blockade and VDA treatments through complementation
and enhancement of the vascular-disrupting effect. To confirm
this hypothesis, we evaluated the influence of CA4P on RhoJ-
WT and KO mice. Treatment with CA4P (50 mg/kg) resulted in
only an 18% reduction in tumor growth of WT mice, in which
the response to CA4P was not maintained and tumors began
to regrow. However, RhoJ-KO mice displayed a 79% additional
inhibition in tumor growth when treated with CA4P, in which a
durable response to CA4Pwas observed. (Figure 8D). Moreover,
CA4P reduced vascular densities by 59% and 60% in the peri-
and intratumoral regions of RhoJ-KO mice, respectively, which
was more potent compared to the respective 13% and 31%
reduction in RhoJ-WT mice (Figures 8E and 8F). Finally, CA4P
displayed an efficient antimetastatic effect in RhoJ-KO mice,
reducing metastasis by 67%, but no reduction in RhoJ-WT
mice (Figures 8G and 8H). Taking these data together, we
confirmed that RhoJ blockade is a valuable complementary ther-
apy to overcome the limitations of current VDA therapy.
DISCUSSION
Here, we have demonstrated a critical role of RhoJ in the regula-
tion of tumor angiogenesis and tumor vascular integrity. The
phenotypic endpoints of RhoJ blockade are similar to those of
the blockade of another small GTPase, R-Ras; genetic disrup-
tion of R-Ras also severely impairs EC barrier function, resulting
in disturbed tumor vasculature maturation (Sawada et al., 2012).
Furthermore, it has recently been reported that RhoJ is strongly
expressed in human cancers, being one of the top ten genes of
the common angiogenesis signature (Masiero et al., 2013). This
correlates well with our data, which show that high expression
of RhoJ in colon cancer is a negative prognostic factor in these
patients, further highlighting RhoJ as a clinically relevant thera-
peutic target in cancer.
RhoJ blockade displayed several advantages over current
vascular targeting therapy, but the most superior advantage is
its ‘‘double assault’’ on tumor vessels. Vascular targeting agents
developed during the past decade are commonly classified as
either AIAs or VDAs. AIAsmainly suppress the formation of tumor
neovessels and induce tumor vessel normalization, whereas
VDAs directly disrupt preformed tumor vessels and shut down
blood flow, finally resulting in massive tumor necrosis and hem-
orrhage (Tozer et al., 2005). AIAs are particularly effective in the
peritumoral regions of newly progressing tumors where new tu-
mor vessels are robustly developing, whereas VDAs are most
effective in the intratumoral regions of an established tumor
where preformed immature vessels are abundant (Horsman
and Siemann, 2006; Siemann, 2011). RhoJ blockade encom-
passes the aspects of AIAs and VDAs and offers an effective
strategy for targeting tumor vasculatures. It simultaneously
impedes the formation of tumor neovessel and disrupts the
pre-established tumor vessel network. Through this ‘‘doubleancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc. 109
Figure 4. RhoJ Deletion Delays Tumor Growth, Neovessel Formation, and Metastasis in the Spontaneous Breast Cancer Model
Tumor growth was analyzed weekly in spontaneous mammary tumors of P/RhoJ-WT and -KO starting from 8 weeks after birth. Samples were harvested
18 weeks after birth. Unless otherwise denoted: scale bars, 100 mm. Each group: n = 5. Values are mean ± SD. *p < 0.05 versus P/RhoJ-WT.
(A) Image showing tumor development at 14 weeks after birth. Dotted lines demarcate palpable mammary tumor nodules.
(legend continued on next page)
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hibited blood flow to tumor cells and displayed a convincing anti-
cancer and antimetastatic effect.
In addition, RhoJ blockade compensates for and augments
other anticancer therapies. The combination therapy of RhoJ
blockade and the conventional chemotherapeutic drug,
cisplatin, proved to be very effective in delaying tumor progres-
sion. As is previously known, the intratumoral core of tumors is
resistant to conventional anticancer therapies (Tre´dan et al.,
2007; Wachsberger et al., 2003), because anticancer drug deliv-
ery to this core is limited and inefficient due to the immature
tumor vessels and increased interstitial pressure (Fukumura
and Jain, 2007). Additionally, tumor cells in the intratumoral
core have an intrinsic resistance to chemotherapy because
they proliferate slowly and the growth fraction is small (Tre´dan
et al., 2007). Intriguingly, RhoJ blockade preferentially induces
vascular shutdown in intratumoral regions, resulting in necrosis
of the tumor cells. By combining cisplatin and the RhoJ
blockade, both of which exert distinctive modes of action, we
achieved a comparatively enhanced antitumor and antimeta-
static effect, which suggests the potential of RhoJ blockade as
an adjuvant for conventional chemotherapies. Moreover, the
combination of RhoJ blockade with VDAs also showed an
enhanced antitumor efficacy. Most VDAs target the tubulin cyto-
skeleton of tumor ECs directly and induce activation of RhoA-
ROCK signaling in tumor ECs, resulting in the rapid and selective
disruption of the preformed tumor vessels (Siemann, 2011).
However, despite promising preclinical results, they failed to
show efficacy in clinical trials (Baguley and McKeage, 2012).
The major drawback of VDAs is that they mainly target the intra-
tumoral core, leaving the remaining peripheral viable rim to
regrow and even acquire resistance to VDAs (Horsman and Sie-
mann, 2006; Tozer et al., 2005). In contrast, RhoJ blockade in the
present study exerted its antitumor effect through inhibition of
neovessel formation in both the peri- and intratumoral regions
and also enhanced shutdown of pre-existing tumor vessels in
the intratumoral regions. Furthermore, we found that RhoJ
blockade shares its actionmechanismwith VDAs, also activating
the RhoA-ROCK signaling pathway. In this regard, it is logical to(B) Comparison of percentage of mice remaining tumor free at indicated time. Ea
(C) Comparison of number of palpable tumor nodules. Each group: n = 8.
(D) Comparison of volumes of each tumor nodule at 18 weeks after birth. Lines i
(E) Comparison of total tumor burden. Tumor burden was calculated by summat
(F) Tumor sections stained with H&E showing peri- and intratumoral regions. Ac
noninvasive malignant lesions in mammary ducts during early tumorigenesis. H
adipose tissue (Adi) is evident. Invasive carcinoma lesions (Ca) that have invaded
hand, the tumors of P/RhoJ-WT have already infiltrated the surrounding tissues
Necrotic region. Scale bars, 500 mm.
(G and H) Images (G) and quantification (H) of blood vessels in the peri- and intra
(I) Comparison of vascular sprouts (>10 mm) per mm2 in the peri- and intratumor
(J and K) Images (J) and quantification (K) of dextran leakage (red) from tumor
presented as a percent per total sectional area.
(L andM) Images (L) and quantification (M) of coverage of PDGFRb+mural cells on
that lies along CD31+ vessels.
(N and O) Images (N) and quantification (O) showing loss of collagen type IV+ BM
percent of length that lies along CD31+ vessels.
(P) Lung sections stained with H&E. Metastatic regions were viewed under high
200 mm (lower).
(Q) Comparison of number of metastatic colonies (>100 mm in diameter) in the lu
See also Figure S4.
Cspeculate that RhoJ blockade may be complementary to current
VDA therapies. Indeed, we confirmed that RhoJ blockade could
overcome the resistance acquired from VDA monotherapies,
such as CA4P, with regard to tumor growth and progression.
Previous studies have found that VEGF-A stimulation regulates
the activity of various Rho GTPases, such as Cdc42, Rac1, and
RhoA, whereas interactions among various Rho GTPases are
poorly understood (Beckers et al., 2010; Bryan and D’Amore,
2007; Schiller, 2006). Blocking the RhoJ pathway over a pro-
longed period raises the possibility of compensatory activation
of other Rho GTPases in tumor vessels, especially by Cdc42
and Rac1, which share common downstream effector molecules
with RhoJ (Leszczynska et al., 2011). From this perspective, the
concurrent inhibition of RhoJ signaling and VEGF-A signaling
could be an attractive therapeutic strategy not only by enhancing
current AIA therapy, but also bymaximizing the vascular-disrupt-
ing effect of the RhoJ blockade. Indeed, our findings strongly
support this possibility. The combination of RhoJ blockade and
VEGF decoy receptor, VEGF-trap, showed comparatively potent
antiangiogenic activity in both peri- and intratumoral areas of the
LLC tumor, which is known to be resistant to conventional AIA
therapies (Shojaei et al., 2007). Another possible benefit from
this combination is that RhoJ blockade may maintain and
maximize responses to the AIA therapies. It is known that tumor
vessels regrow alongside the ghost tracks of remnant BM after
cessation or during the resting period of AIA treatment (Mancuso
et al., 2006). Intriguingly, we observed a severe loss of BM in
RhoJ-deficient tumor vessels, indicating that concurrent RhoJ
blockade might abolish remnant BM in concert with AIAs and
prevent tumor vessel from regrowth, finally resulting in a
sustained response to the AIA therapies.
An additional advantage of RhoJ blockade is that it selectively
targets tumor vessels with minimal systemic side effects.
Current AIAs influence normal vessels as well, because their
main targets, VEGF-A and its receptors, are expressed ubiqui-
tously. Therefore, they induce systemic side effects such as
hemorrhage, hypertension, proteinuria, and delayed wound
healing (Chen and Cleck, 2009; Kamba and McDonald, 2007).
On the other hand, RhoJ expression is very specific to pathologicch group: n = 8.
ndicate mean and standard deviation. Each group: n = 20.
ing the volume of tumor nodules per mice. Each group: n = 8.
inar structures of P/RhoJ-KO are ductal carcinoma in situ (DCIS), which are
ere, the boundary (black line) between DCIS and the surrounding mammary
into the neighboring stroma are also observable beside the DCIS. On the other
and formed solid sheets of tumor cells with little or no DCIS remaining. Nec,
tumoral regions.
al regions.
vessels. Dextran was i.v.-injected 30 min before sacrifice. Dextran+ area is
CD31+ tumor vessels. Coverage of PDGFRb is presented as a percent of length
along CD31+ tumor vessels. Coverage of collagen type IV is presented as a
magnification. Arrows indicate metastatic foci. Scale bars, 5 mm (upper) and
ng sections. Each group: n = 8.
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Figure 5. EC-Specific Ablation of RhoJ Suppresses Tumor Angiogenesis and Induces Vascular Disruption
(A–L) Histological and functional analyses were performed 16 days after implantation of LLC cells into RhoJ-WTEC and -KOEC. Mice were treated with i.p.
injections of tamoxifen (4 mg/kg) four times every 2 days starting from the day before tumor implantation. Unless otherwise denoted: scale bars, 100 mm. Each
group: n = 5. Values are mean ± SD. *p < 0.05 versus RhoJ-WTEC.
(A) Comparisons of LLC tumor growth.
(B) Images of tumor sections stained with H&E. Dotted lines demarcate intratumoral hemorrhagic area. Scale bar, 5 mm.
(C) Comparison of intratumoral hemorrhage area.
(D) Comparison of viable area in cross sections.
(E andF) Images (E) andquantification (F) ofCD31+blood vessels in theperi- and intratumoral regions.Dotted lines indicateboundariesbetween theskin and tumor.
(G and H) Images (G) and quantification (H) of coverage of PDGFRb+ mural cells along CD31+ tumor vessels. Coverage of PDGFRb is presented as a percent of
length that lies along CD31+ vessels.
(I and J) Images (I) and quantification (J) of loss of collagen type IV+ BM along CD31+ tumor vessels. Coverage of collagen type IV is presented as a percent of
length that lies along CD31+ vessels.
(K and L) Images (K) and quantification (L) of dextran leakage area (green) from tumor vessels. Dextran was i.v.-injected 30 min before sacrifice. Dextran+ area is
presented as a percent per total sectional area.
(M and N) RhoJ-WTEC and -KOEC were treated with i.p. injections of tamoxifen (4 mg/kg) four times on the indicated days (arrows), after the tumor volume had
exceeded 300 mm3. Each group: n = 10.
(M) Comparison of LLC tumor growth. *p < 0.05 versus RhoJ-WTEC.
(N) Comparison of overall survival after tamoxifen injection. p = 0.016 by log rank.
See also Figure S5.
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pressed in organs under normal physiologic conditions; the
global deletion of RhoJ does not induce gross abnormalities
and lethality. However, our results indicate that RhoJ plays a
positive angiogenic role during wound healing, and this could
be an unavoidable side effect of a putative RhoJ inhibitor.
Finally, RhoJ is a feasible target for clinical drug development.
We could therapeutically target RhoJ in tumor tissues through an112 Cancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc.in vivo siRNA delivery system. Using the APTEDB-LS complex as
a carrier, which has high specificity against tumor tissues (Kim
et al., 2012), we effectively delivered siRhoJ into tumor tissues
and significantly delayed tumor growth and metastasis, espe-
cially in concert with VEGF-trap. Consequently, we established
a way to clinically inhibit RhoJ.
In conclusion, our evidence shows that RhoJ is a promising
selective target in the tumor vasculature that governs the
Figure 6. RhoJ Regulates EC Motility, Tube Formation, and Integrity through Suppression of the RhoA-ROCK Signaling Pathway
HUVECs were transfected with either control siRNA (siC-ECs) or RhoJ siRNA (siJ-ECs). Unless otherwise denoted: scale bars, 100 mm. Each group: n = 5. Values
are mean ± SD. *p < 0.05 versus siC-ECs.
(A and B) Random migration of ECs was tracked with time-lapse microscopy for 6 hr. (A) Trajectory images showing locomotion of individual ECs. (B) Com-
parisons of EC migratory speed.
(C and D) siC-ECs and siJ-ECswere seeded into the 3Dmicrofluidics system, in which ECsmigrate and sprout along growth factor gradient for 3 days. (C) Images
showing directional migration and sprouting of ECs. Solid line, starting point; dotted line, point of maximal migration. (D) Comparisons of maximal distance of EC
migration and EC sprouting (>10 mm in length).
(E–G) siC-ECs and siJ-ECs were seeded on Matrigel and incubated for 12 hr. (E) Images showing EC tube formation. (F) Comparisons of number of EC junctions
and tubules. (G) Images showing F-actin fibers (red) in EC tubules. Arrows indicate collapse of ECs and increased actin stress fiber. Indicated region (square) is
magnified in the right panel.
(H) Images showing F-actin fiber in LLC tumor 16 days after tumor implantation into RhoJ-WTEC and -KOEC. Arrows indicate increased actin stress fiber in tumor
vessels. Indicated region (square) is magnified in the right panel.
(I and J) siC-ECs or siJ-ECs were cultured on cell inserts until an EC monolayer formed. Subsequently, the amount of dextran permeated across the monolayer
with or without VEGF-A (50 ng/ml) was measured. (I) Schematic diagram showing in vitro permeability assay. (J) Comparison of vascular permeability across EC
monolayer. *p < 0.05 versus siC-EC+PBS.
(K and L) siC-ECs or siJ-ECs were cultured on culture plates until an EC monolayer formed. Consecutively, the ECs were incubated with or without VEGF-A
(50 ng/ml) for 1 hr. (K) CD144 junctions of EC monolayer in various conditions. (L) Electron microscopic images of EC monolayer in various conditions. Arrows
indicate spatial gaps between adjacent ECs. Scale bars, 5 mm.
(M) Immunoblotting showing modulation of RhoA-ROCK signaling pathway by RhoJ. siC-ECs or siJ-ECs were cultured for 24 hr, and treated with or without
Y-27632 (20 mM) for 1 hr. Three independent experiments show similar results.
(N) Schematic diagram showing the role of endothelial RhoJ. When RhoJ is activated in ECs, RhoJ suppresses RhoA-ROCK signaling, while activating N-WASP
and PAK, which reorganize the cortical actin filaments in ECs. Upon RhoJ knockdown, RhoA-ROCK signaling is no longer suppressed in ECs, therefore inducing
EC contraction through increased formation of actin stress fibers, eventually causing vascular shutdown. N-WASP, Neural Wiskott-Aldrich syndrome protein;
PAK, p21-activated kinase.
See also Figure S6.
Cancer Cell
Targeting RhoJ for Tumor Vascular Disruptionprocesses of tumor angiogenesis and vascular integrity. The
distinguishing characteristics of RhoJ blockade provide a
strategy for overcoming the limitations of current vascularCtargeting therapies in patients with advanced cancer. Further
development of specific RhoJ inhibitors is needed to ascertain
their efficacy and safety in clinical settings.ancer Cell 25, 102–117, January 13, 2014 ª2014 Elsevier Inc. 113
Figure 7. Dual Blockade of RhoJ and VEGF Signaling Suppresses Tumor Progression and Metastasis
(A–C) LLC implanted RhoJ-WT or -KO mice were given injections of VEGF-trap (VT) or Fc on the indicated days (arrows). Tumors were sampled 9 days after the
first treatment. Scale bars, 100 mm. Each group: n = 5. Values are mean ± SD. *p < 0.05 versus WT, Fc; #p < 0.05 versus WT, VT.
(A) Comparison of tumor growth.
(legend continued on next page)
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Figure 8. RhoJ Blockade Augments the Anti-Tumor Effect of a VDA, Combretastatin-A4-Phosphate (CA4P)
Unless otherwise denoted: scale bars, 100 mm. Values are mean ± SD.
(A and B) siC-ECs and siJ-ECswere seeded onMatrigel with or without CA4P (20 nM) and incubated for 12 hr. *p < 0.05 versus siC-EC+PBS; #p < 0.05 versus siC-
EC+CA4P.
(C) siC-ECs and siJ-ECs were cultured on cell inserts until an EC monolayer formed. The results of dextran permeation across the EC monolayer for 20 min was
compared. *p < 0.05 versus siC-EC+PBS; #p < 0.05 versus siC-EC+CA4P.
(D–H) LLC implanted RhoJ-WT or -KO mice were given i.p. injections of CA4P (50 mg/kg) or PBS on the indicated days (arrows). Tissues were sampled 6 days
after the first treatment. Each group: n = 5. *p < 0.05 versus WT, PBS; #p < 0.05 versus WT, CA4P.
(D) Comparison of tumor growth. $p < 0.05 versus KO, PBS.
(E and F) Images (E) and quantification (F) of tumor vessels in the peri- and intratumoral regions.
(G and H) Images (G) and quantification (H) of metastasized cytokeratin+ tumor cells (red) to inguinal LNs. Cytokeratin+ area is presented as percent per total
sectional area. Scale bar, 500 mm.
See also Figure S8.
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Mice
Animal care and experimental procedures were performed under the approval
(KA2011-17) of the Animal Care Committee of the Korea Advanced Institute
of Science and Technology. Specific pathogen-free (SPF) C57BL/6J and(B and C) Images (B) and quantification (C) of tumor vessels in peri- and intratum
(D–J) LLC implanted WT mice were given injection of either VT or Fc together wi
harvested 12 days after the first treatment. Scale bars, 100 mm. Each group: n =
(D) Comparison of tumor growth.
(E and F) Images (E) and quantification (F) of tumor vessels in peri- and intratum
(G and H) Images (G) and quantification (H) of intratumoral hemorrhage. $p < 0.0
(I and J) Images (I) and quantification (J) of metastasized cytokeratin+ tumor cell
sectional area. Scale bar, 500 mm.
See also Figure S7.
CMMTV-PyMT transgenic mice (FVB/N) were purchased from Jackson Labora-
tory. RhojGFP/GFP and Rhojfl/fl mice and Cdh5(PAC)-CreERT2mice (Wang et al.,
2010) were transferred and bred in our SPF facilities. To depleteRhoj inMMTV-
PyMT tumors, RhojGFP/GFP female mice were intercrossed with MMTV-PyMT
male mice. To deplete Rhoj specifically in ECs, Rhojfl/flmice were intercrossed
with Cdh5(PAC)-CreERT2 mice. All mice were fed with ad libitum access tooral areas. Dotted lines indicate the boundaries between the skin and tumor.
th either en-siC or en-siJ on the indicated days (arrows). Tissue samples were
5. *p < 0.05 versus en-siC+Fc; #p < 0.05 versus en-siC+VT.
oral regions.
5 versus en-siJ+Fc. Scale bar, 5 mm.
s (red) to the inguinal LNs. Cytokeratin+ area is presented as percent per total
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Targeting RhoJ for Tumor Vascular Disruptionstandard diet (PMI Lab diet) and water. All mice were anesthetized by intra-
muscular injection of a combination of anesthetics (80 mg/kg of ketamine
and 12 mg/kg of xylazine) before being sacrificed.
Tumor Models and Treatment Regimens
LLC and B16F10 melanoma cells were obtained from American Type Culture
Collection. To generate implantation tumormodels, suspensions of tumor cells
(13 106 cells in 100 ml) were s.c. injected into the dorsal flank of 8- to 10-week-
old mice. Tumor volumes were measured at given time points. Tumor volume
was calculated according to the formula 0.5 3 A 3 B2, where A is the largest
diameter of a tumor and B is its perpendicular diameter. Tumor growth rate is
defined as increased tumor volume relative to 2 days before. Indicated days
later, the mice were anesthetized and tissues were harvested for further ana-
lyses. Tamoxifen (4 mg/kg four times every 2 days, Sigma-Aldrich) was i.p.
injected into Cdh5(PAC)-CreERT2;Rhojfl/fl mice starting from the day before
tumor implantation or after the tumor volume had exceeded 300 mm3.
Cisplatin (10 mg/kg every 7 days, Sigma-Aldrich) was i.p. injected for cytotoxic
chemotherapy when tumor volume exceeded 100mm3. VEGF-trap (25 mg/kg,
indicated schedule) was s.c. injected as an AIA therapy. CA4P (50mg/kg every
2 days, Sigma-Aldrich) was i.p. injected as a VDA therapy. As a control, equal
amounts of Fc or PBS were injected in the samemanner. To knock down RhoJ
in vivo, control or RhoJ siRNA (2 mg/kg, indicated schedule), which were
encapsulated into APTEDB-LS complexes, were i.v. injected into tumor-
bearing mice.
Human Tumor Specimens
All human samples were collected by the tissue bank of Severance Hospital,
Seoul, Korea, with the informed consents from the donors following the
bioethics and safety regulations. All procedures regarding human samples
wereperformedwith theapproval of the institutional reviewboard (KH2013-02).
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